Whitehawk Therapeutics Showcases Promising Real-World Data on MUC16 for Ovarian Cancer at IGCS 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage company dedicated to advancing oncology therapeutics, unveiled compelling real-world analyses substantiating the therapeutic potential of mucin 16 (MUC16) as a durable target for antibody-drug conjugate (ADC) applications in ovarian cancer. These significant findings were shared during the International Gynecologic Cancer Society (IGCS) Annual Global Meeting from October 1 to October 3, 2026, held in Montreal, Canada. The analyses focused on MUC16 expression levels in tumor samples collected from patients undergoing various standard-of-care therapies for ovarian cancer. Remarkably, results indicated that MUC16 retention remained high and substantially stable even after treatments that include platinum-based chemotherapy, non-platinum regimens, bevacizumab combinations, PARP inhibitors, and mirvetuximab soravtansine. Unlike other ADC targets such as FRα, TROP2, and NaPi2b, MUC16 displayed minimal treatment-induced fluctuations in expression. This suggests a promising rationale for pursuing MUC16 as a viable target for multiple lines of therapy, particularly in relapsed disease scenarios.
Dr. Margaret Dugan, Chief Medical Officer at Whitehawk, remarked, "It is crucial for an ADC target in ovarian cancer to maintain consistent expression across various treatment lines. Our findings support the notion that MUC16 remains steady throughout the treatment spectrum, thus reinforcing the exploration of HWK-016 alongside existing therapies and for patients experiencing disease progression after earlier interventions."
In a further investigation concentrated on high-grade serous ovarian carcinoma (HGSOC), the leading subtype accounting for roughly 70% of ovarian cancer cases, high levels of MUC16 were found to correlate with poorer overall survival outcomes in real-world settings. This correlation persisted even after adjusting for key clinical and molecular factors, as well as in treatment-naïve patients presenting with metastatic disease. Dr. Robert L. Coleman of Texas Oncology commented, "Ovarian cancer remains a challenging disease to treat, which necessitates innovative therapeutic strategies. The revelation that higher MUC16 expression is associated with more aggressive disease underscores its importance as a malignant biology marker, thus advocating for the ongoing investigation of MUC16-targeted ADCs."
Key Poster Details:
Title: Durable and Treatment-Agnostic MUC16 Expression in Ovarian Cancer Supports Targeted Antibody-Drug Conjugate Development
Presenter: Dr. Kathleen N. Moore, University of Nebraska Medical Center, Omaha, Nebraska
Date/Time: E-Poster Presentation
Notable Findings:
- MUC16 expression retained stability across various therapies, including both chemotherapy types and other treatments.
- The results indicate that MUC16 could potentially be targeted further in therapeutic sequences post-standard treatment regimens, as well as in combination with initial platinum-based therapies.
- Stability of MUC16 was corroborated in matched tumor samples collected sequentially over the course of treatment.
Title: High MUC16 Expression Is Associated With Poor Real-World Overall Survival in Patients With High-Grade Serous Ovarian Carcinoma
Presenter: Dr. Robert L. Coleman, Texas Oncology, The Woodlands, Texas
Date/Time: October 1, 2026, 2:35-2:40 PM ET
Notable Findings:
- MUC16 levels at first metastatic diagnosis corresponded significantly with poorer overall survival outcomes.
- The correlation was also noted in the subpopulation that had not previously undergone treatment.
- Other independent prognostic indicators included performance status, BRCA mutation status, and diagnosis age, thus enhancing understanding of prognostic paradigms in HGSOC.
The investigational ADC, HWK-016, specifically targets the non-shed extracellular domain of MUC16 and is undergoing evaluation in a Phase 1 clinical trial involving patients with advanced ovarian and endometrial cancers. This analysis stems from a collaboration between Whitehawk and Tempus AI.
Whitehawk Therapeutics is committed to redefining cancer treatment through their innovative ADC platform, which includes promising assets such as HWK-007, HWK-016, and HWK-206. These drugs are crafted to transcend the limitations of first-generation ADCs and aim to deliver remarkable benefits for patients facing challenging cancer diagnoses. To learn more, visit www.whitehawktx.com. The company emphasizes that the information on its website does not constitute guidance for investors; they are encouraged to refer to official filings for reliable updates regarding the company's evolutions and projections.
As Whitehawk Therapeutics forges ahead, it remains dedicated to unlock new routes for treatment in oncology, driven by rigorous research and collaborative endeavors that promise a healthier outlook for patients affected by malignancies such as ovarian cancer.
Dr. Margaret Dugan, Chief Medical Officer at Whitehawk, remarked, "It is crucial for an ADC target in ovarian cancer to maintain consistent expression across various treatment lines. Our findings support the notion that MUC16 remains steady throughout the treatment spectrum, thus reinforcing the exploration of HWK-016 alongside existing therapies and for patients experiencing disease progression after earlier interventions."
In a further investigation concentrated on high-grade serous ovarian carcinoma (HGSOC), the leading subtype accounting for roughly 70% of ovarian cancer cases, high levels of MUC16 were found to correlate with poorer overall survival outcomes in real-world settings. This correlation persisted even after adjusting for key clinical and molecular factors, as well as in treatment-naïve patients presenting with metastatic disease. Dr. Robert L. Coleman of Texas Oncology commented, "Ovarian cancer remains a challenging disease to treat, which necessitates innovative therapeutic strategies. The revelation that higher MUC16 expression is associated with more aggressive disease underscores its importance as a malignant biology marker, thus advocating for the ongoing investigation of MUC16-targeted ADCs."
Key Poster Details:
Title: Durable and Treatment-Agnostic MUC16 Expression in Ovarian Cancer Supports Targeted Antibody-Drug Conjugate Development
Presenter: Dr. Kathleen N. Moore, University of Nebraska Medical Center, Omaha, Nebraska
Date/Time: E-Poster Presentation
Notable Findings:
- MUC16 expression retained stability across various therapies, including both chemotherapy types and other treatments.
- The results indicate that MUC16 could potentially be targeted further in therapeutic sequences post-standard treatment regimens, as well as in combination with initial platinum-based therapies.
- Stability of MUC16 was corroborated in matched tumor samples collected sequentially over the course of treatment.
Title: High MUC16 Expression Is Associated With Poor Real-World Overall Survival in Patients With High-Grade Serous Ovarian Carcinoma
Presenter: Dr. Robert L. Coleman, Texas Oncology, The Woodlands, Texas
Date/Time: October 1, 2026, 2:35-2:40 PM ET
Notable Findings:
- MUC16 levels at first metastatic diagnosis corresponded significantly with poorer overall survival outcomes.
- The correlation was also noted in the subpopulation that had not previously undergone treatment.
- Other independent prognostic indicators included performance status, BRCA mutation status, and diagnosis age, thus enhancing understanding of prognostic paradigms in HGSOC.
The investigational ADC, HWK-016, specifically targets the non-shed extracellular domain of MUC16 and is undergoing evaluation in a Phase 1 clinical trial involving patients with advanced ovarian and endometrial cancers. This analysis stems from a collaboration between Whitehawk and Tempus AI.
Whitehawk Therapeutics is committed to redefining cancer treatment through their innovative ADC platform, which includes promising assets such as HWK-007, HWK-016, and HWK-206. These drugs are crafted to transcend the limitations of first-generation ADCs and aim to deliver remarkable benefits for patients facing challenging cancer diagnoses. To learn more, visit www.whitehawktx.com. The company emphasizes that the information on its website does not constitute guidance for investors; they are encouraged to refer to official filings for reliable updates regarding the company's evolutions and projections.
As Whitehawk Therapeutics forges ahead, it remains dedicated to unlock new routes for treatment in oncology, driven by rigorous research and collaborative endeavors that promise a healthier outlook for patients affected by malignancies such as ovarian cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.